Detail of "34089-81-1"

Reference

Transferrin saturation with intravenous irons: an in vitro study

Some chemicals with cas registry numbers like 34089-81-1 and 8047-67-4 are also used. Transferrin saturation with intravenous irons: an in vitro study. Agarwal, Rajiv (Department of Medicine, VA Medical Center, Indiana University School of Medicine, Indianapolis, IN, USA). Kidney International, 66(3), 1139-1144 (English) 2004 Blackwell Publishing, Inc. CODEN: KDYIA5. ISSN: 0085-2538. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Background: Iron deficiency anemia in chronic kidney disease is commonly treated with one of three i.v. irons-iron dextran, iron sucrose, or iron gluconate. Substantial pharmacol. differences between drugs exist, but their ability to sat. transferrin has not been compared. Drugs that may lead to rapid transferrin satn. may lead to greater efficacy but also increased toxicity if transferring-mediated uptake of iron is the basis of this toxicity. Methods: We studied the in vitro ability of the three i.v. irons to donate iron to transferrin. Transferrin satn. was studied by direct visualization of the transferrin bands by urea PAGE, as well as a functional assay that evaluated the ability of iron to half sat. transferrin in a dose-dependent (0 to 100 mg/mL) and time-dependent (15 to 180 min) manner. Half-maximal dose (EC50) of iron needed to sat. transferrin was evaluated. Results: Nondextran irons were able to sat. transferrin in a dose-dependent and time-dependent manner. There was more rapid transferrin satn. with iron gluconate compared to iron sucrose. The slope of the EC50 vs. dose iron gluconate titrn. curve was -0.021 nmol/mg/mL (95% CI -0.025 to -0.017, P < 0.0001), for iron sucrose -0.006 nmol/mg/mL (95% CI -0.010 to -0.002, P = 0.002), and for iron dextran -0.001 nmol/mg/mL (95 % CI -0.004 to 0.003, P > 0.2). The least square mean EC50 computed for mean iron concn. was 5.95 nmol for iron gluconate (95% CI 5.82 to 6.08), 6.73 nmol for iron sucrose (95% CI 6.59 to 6.86), and 7.24 nmol for iron dextran (95% CI 7.11 to 7.38). Similar results were seen for the time-dependent transferrin satn. (drug ′ time interaction, F 6.0, P < 0.01). Urea PAGE anal. showed similar results as the functional assay. Conclusion: Substantial heterogeneity in direct iron transfer from iron pharmaceuticals in vitro suggests that differences may exist in safety and efficacy of these drugs in vivo. In vivo studies are needed to compare the safety and efficacy of existing nondextran parenteral irons to better define the therapeutic ratio. .